Auteurs
[:fr]Francesco Puleo[:],
[:fr]Jeremy Augustin[:],
[:fr]Jean-Francois Emile[:],
[:fr]Magali Svrcek[:],
[:fr]Tatjana Arsenijevic[:],
[:fr]Jean-Luc Van Laethem[:],
[:fr]Jean-Baptiste Bachet[:],
Abstract
Background
Few patients with pancreatic adenocarcinoma (PAC) are eligible for surgery. Patients with early relapse have a poor prognosis and might be better candidates for a medical approach. Clinical and pathological parameters only partially predict recurrence and are only obtained after surgery. PAC subtypes based on gene expression were proposed, and we assessed if they could predict the risk and type of recurrence independently of clinicopathological parameters.
Methods
Patients with curative-intent surgery for PAC without pretreatment were selected and divided into two independent cohorts defined as discovery (n = 381) and validation (n = 149) cohorts. Transcriptomic analyses were performed on formalin-fixed paraffin-embedded surgical samples to characterise tumour and stroma compartments using previously defined signatures. We associated molecular and clinicopathological characteristics with general, distant, and local recurrences using Cox regression analyses.
Results
We found that tumour biology predicted distant recurrence contrary to local recurrence, which was directly related to resection margin status. Pure basal-like and stroma-activated subtypes were strongly associated with distant recurrence, independently of clinicopathological factors (hazard ratios [HRs] = 5.85, p < 0.001 and HR = 1.75, p = 0.007, respectively). By dissecting tumoural and stromal compartments, we demonstrated that the basal-like tumour component positively correlated with distant recurrence in both cohorts (HR = 1.45, p < 0.001 and HR = 1.90, p < 0.001), whereas the inactive structural stroma component was protective against distant recurrence (HR = 0.68, p < 0.001 and HR = 0.72, p < 0.001).
Conclusions
In addition to suggesting a different mechanism for local and distant relapse (incomplete resection and high metastatic potential, respectively), our results show the potency of molecular phenotype to predict patient outcome regarding distant recurrences.
Autres publications
Date de publication :
11 Fév 2025Auteurs :
Hilmi Marc,
Flore Delecourt,
Raffenne Jérome,
Bourega Taib,
Nelson Dusetti,
Juan Iovanna,
Yuna Blum,
Magali Richard,
Cindy Neuzillet,
Couvelard Anne,
Matthieu Tihy,
De Mestier Louis,
Rebours Vinciane,
Nicolle Rémy,
Cros Jérome,
Date de publication :
04 Oct 2024Auteurs :
Yohann Loriot,
Maud Kamal,
Laurene Syx,
Nicolle Rémy,
Celia Dupain,
Naoual Mensourri,
Igor Duquesne,
Pernelle Lavaud,
Claudio Nicotra,
Maud Ngocamus,
Ludovic Lacroix,
Lambros Tselikas,
Gilles Crehange,
Luc Friboulet,
Zahra Castel-Ajgal,
Yann Neuzillet,
Edith Borcoman,
Philippe Beuzeboc,
Grégoire Marret,
Tom Gutman,
Jennifer Wong,
Francois Radvanyi,
Sylvain Dureau,
Jean-Yves Scoazec,
Nicolas Servant,
Yves Allory,
Benjamin Besse,
Fabrice Andre,
Christophe Le Tourneau,
Christophe Massard,
Ivan Bieche,
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy
Lancet Gastroenterol Hepatol.
Date de publication :
01 Déc 2023Auteurs :
Hilmi Marc,
Matthieu Delaye,
Milena Muzzolini,
Nicolle Rémy,
Cros Jérome,
Hammel Pascal,
Victoire Cardot-Ruffino,
Cindy Neuzillet,
Date de publication :
14 Nov 2023Auteurs :
Nicolle Rémy,
Jean-Baptiste Bachet,
Alexandre Harlé,
Juan Iovanna,
Hammel Pascal,
Rebours Vinciane,
Anthony Turpin,
Meher Ben Abdelghani,
Alice Wei,
Emmanuel Mitry,
Anthony Lopez,
James Biagi,
Eric François,
Pascal Artru,
Aurélien Lambert,
Daniel J Renouf,
Laure Monard,
Marjorie Mauduit,
Nelson Dusetti,
Thierry Conroy,
Cros Jérome,

